Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%

Healthcare

Page 96
  1. Nov 24, 2025 · 09:05 · SPLY

    Safe Supply Secures Exclusive Canadian Rights to Healthy Sprays' Proprietary GLP-1 Delivery Technology; Announces Non-Brokered Private Placement

    Safe Supply Secures Exclusive Canadian Rights to Healthy Sprays' Proprietary GLP-1 Delivery Technology; Announces Non-Brokered Private Placement

    01
  2. Nov 24, 2025 · 09:01 · TTI

    Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis

    Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis

    02
  3. Nov 24, 2025 · 07:06 · NGEN

    NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

    NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

    03
  4. Nov 24, 2025 · 07:05 · BHC

    Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes

    Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes

    04
  5. Nov 24, 2025 · 07:02 · TLT

    Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    05
  6. Nov 24, 2025 · 07:02 · NGEN

    NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

    NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

    06
  7. Nov 24, 2025 · 06:00 · RKV

    Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting

    Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting

    07
  8. Nov 24, 2025 · 04:00 · RKV

    Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

    Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

    08
  9. Nov 21, 2025 · 18:03 · DTC

    Defence Therapeutics Announces Convertible Debenture Conversion

    Defence Therapeutics Announces Convertible Debenture Conversion

    09
  10. Nov 21, 2025 · 18:01 · FNDX

    FendX Provides Corporate Update

    FendX Provides Corporate Update

    10
  11. Nov 21, 2025 · 17:53 · CNVI

    Conavi files prospectus for share offering

    Conavi files prospectus for share offering

    11
  12. Nov 21, 2025 · 16:56 · RVV

    Revive talks DRDC study on bucillamine for nerve agents

    Revive talks DRDC study on bucillamine for nerve agents

    12
  13. Nov 21, 2025 · 16:30 · CNVI

    Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

    Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

    13
  14. Nov 21, 2025 · 12:07 · RVV

    Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

    Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

    14
← Newer Older →